FDA to use Ingenuity Pathways Analysis for Review of Pharmacogenomics Data | GenomeWeb

NEW YORK, June 21 (GenomeWeb News) - Ingenuity said today that the US Food and Drug Administration has licensed its Ingenuity Pathways Analysis platform for use in the review of pharmacogenomics data submissions. 


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.